A review of health care models for coronary heart disease interventions

被引:18
作者
Cooper K. [1 ]
Brailsford S.C. [2 ]
Davies R. [3 ]
Raftery J. [1 ]
机构
[1] Wessex Institute for Health Research and Development, University of Southampton, Southampton, Hants SO16 7PX, Highfield
[2] School of Management, University of Southampton, Southampton, Hants SO17 1BJ, Highfield
[3] Warwick Business School, Warwick University
关键词
Coronary heart disease; Decision tree; Discrete event simulation; Economic evaluation; Health care; Markov; Model;
D O I
10.1007/s10729-006-9996-x
中图分类号
学科分类号
摘要
This article reviews models for the treatment of coronary heart disease (CHD). Whereas most of the models described were developed to assess the cost effectiveness of different treatment strategies, other models have also been used to extrapolate clinical trials, for capacity and resource planning, or to predict the future population with heart disease. In this paper we investigate the use of modelling techniques in relation to different types of health intervention, and we discuss the assumptions and limitations of these approaches. Many of the models reviewed in this paper use decision tree models for acute or short term interventions, and Markov or state transition models for chronic or long term interventions. Discrete event simulation has, however, been used for more complex whole system models, and for modelling resource-constrained interventions and operational planning. Nearly all of the studies in our review used cohort-based models rather than population based models, and therefore few models could estimate the likely total costs and benefits for a population group. Most studies used de novo purpose built models consisting of only a small number of health states. Models of the whole disease system were less common. The model descriptions were often incomplete. We recommend that the reporting of model structure, assumptions and input parameters is more explicit, to reduce the risk of biased reporting and ensure greater confidence in the model results. © 2006 Springer Science + Business Media, LLC.
引用
收藏
页码:311 / 324
页数:13
相关论文
共 131 条
[1]  
Elixhauser A., Luce B.R., Taylor W.R., Reblando J., Health care CBA/CEA: An update on the growth and composition of the literature, Med Care, 31, 7 SUPPL., (1993)
[2]  
Elixhauser A., Halpern M., Schmier J., Luce B.R., Health care CBA and CEA from 1991 to 1996: An updated bibliography, Med Care, 36, 5 SUPPL., (1998)
[3]  
Kupersmith J., Holmes-Rovner M., Hogan A., Rovner D., Gardiner J., Cost-effectiveness analysis in heart disease, Part II: Preventive therapies, Prog Cardiovasc Dis, 37, 4, pp. 243-271, (1995)
[4]  
Kupersmith J., Holmes-Rovner M., Hogan A., Rovner D., Gardiner J., Cost-effectiveness analysis in heart disease, Part I: General principles, Prog Cardiovasc Dis, 37, 3, pp. 161-184, (1994)
[5]  
Kupersmith J., Holmes-Rovner M., Hogan A., Rovner D., Gardiner J., Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias, Prog Cardiovasc Dis, 37, 5, pp. 307-346, (1995)
[6]  
Guide to the Methods of Technology Appraisal, (2004)
[7]  
Fagan T., Sunthareswaren R., Crash Course: Cardiovascular System, 2nd Edition, (2002)
[8]  
Torrance G.W., Feeny D., Utilities and quality-adjusted life years, Int J Technol Assess Health Care, 5, 4, pp. 559-575, (1989)
[9]  
Evans C., Tavakoli M., Crawford B., Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal, Health Care Manag Sci, 7, 1, pp. 43-49, (2004)
[10]  
Russell L.B., Gold M.R., Siegel J.E., Daniels N., Weinstein M.C., The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine, JAMA, 276, 14, pp. 1172-1177, (1996)